Testosterone Effects On Renal Norepinephrine Content and Release in Rats With Different Y Chromosomes by Jones, Thomas J. et al.
The University of Akron
IdeaExchange@UAkron
Biology Faculty Research Biology Department
11-1998
Testosterone Effects On Renal Norepinephrine
Content and Release in Rats With Different Y
Chromosomes
Thomas J. Jones
Gail Dunphy
Amy Milsted
University of Akron Main Campus, milsted@uakron.edu
Daniel Ely
University of Akron Main Campus
Please take a moment to share how this work helps you through this survey. Your feedback will be
important as we plan further development of our repository.
Follow this and additional works at: http://ideaexchange.uakron.edu/biology_ideas
Part of the Biology Commons
This Article is brought to you for free and open access by Biology Department at IdeaExchange@UAkron, the
institutional repository of The University of Akron in Akron, Ohio, USA. It has been accepted for inclusion in
Biology Faculty Research by an authorized administrator of IdeaExchange@UAkron. For more information, please
contact mjon@uakron.edu, uapress@uakron.edu.
Recommended Citation
Jones, Thomas J.; Dunphy, Gail; Milsted, Amy; and Ely, Daniel, "Testosterone Effects On Renal Norepinephrine
Content and Release in Rats With Different Y Chromosomes" (1998). Biology Faculty Research. 28.
http://ideaexchange.uakron.edu/biology_ideas/28
Testosterone Effects on Renal Norepinephrine Content and
Release in Rats With Different Y Chromosomes
Thomas J. Jones, Gail Dunphy, Amy Milsted, Daniel Ely
Abstract—The Y chromosome in spontaneously hypertensive rats (SHR) and stroke-prone rats has been shown to contain
a locus that contributes to the hypertensive effect; both the sympathetic nervous system and testosterone may be
involved. The objective of this study was to look at the effects of testosterone on renal norepinephrine (NE) release and
content in the isolated perfused kidney in different Y chromosome backgrounds. The study involved male SHR,
Wistar-Kyoto rats (WKY), and 2 consomic strains with different Y chromosomes (n55 to 8 per group). Adult animals
were castrated, and implants containing testosterone propionate were placed at the base of the neck. Blood testosterone
levels were measured by radioimmunoassay 2 weeks after castration. The left kidney was isolated and perfused with
oxygenated Krebs solution at a constant flow and temperature with KCl and electrical stimulation of the renal nerves.
Perfusate was collected and analyzed for NE by high-performance liquid chromatography. Lactate dehydrogenase
analyses were performed as a marker for potential tissue damage. Renal perfusate and renal tissue NE levels were
significantly elevated by testosterone. The average NE increase with a single testosterone implant was 13.2 ng/mL, and
for a double testosterone implant it was 29.8 ng/mL. The Y chromosome from the SHR produced a significant increase
in renal NE release compared with the WKY Y chromosome. Significance was shown between all groups: 1 versus 2
implants, P50.0067; 1 versus sham implants, P50.015; 2 versus sham implants, P,0.001. In conclusion, testosterone
caused an enhanced renal NE release that was strain-specific, with the Y chromosome raising renal NE content
and release. (Hypertension. 1998;32:880-885.)
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The tendency for males to have a greater incidence ofhypertension than females1–3 in most mammalian species,
at least until menopause (humans), has led to the implication
of sex steroids as a possible hormonal component in the
development and maintenance of essential hypertension.4 The
sympathetic nervous system (SNS) has also been implicated
in some forms of hypertension through increased release of
norepinephrine (NE) and increased tissue NE content and
turnover.5–11 Our laboratory is interested in testosterone, the
SNS, and their interactions as major players in the evolution
and development of high blood pressure. Recently, we
showed that the Y chromosome from spontaneously hyper-
tensive rats (SHR) when back-crossed into Wistar-Kyoto rats
(WKY) increases blood pressure and SNS indicators.12 The
kidney appears to be a target organ for androgens. Testoster-
one dramatically increases kidney weight.13 When a female
SHR kidney is transplanted to a male SHR, the kidney
morphologically and physiologically responds like a male
kidney.14,15 Steroid binding receptors have been biochemi-
cally and audioradiographically demonstrated in the rat renal
proximal tubule,16 and anatomic sex differences exist in the
proximal tubule that change after castration.17
Therefore, the hypothesis tested was that testosterone
would increase the amount of NE released from the kidney
and that the SHR Y chromosome would be associated with a
greater increase and storage of NE in the presence of
testosterone than the Y chromosome from WKY.
Methods
SHR and WKY were obtained originally from Harlan Sprague-
Dawley (Indianapolis, Ind) and since 1981 have been inbred at The
University of Akron. Two consomic strains were developed at The
University of Akron to study the role of the Y chromosome in
hypertension. The SHR/y strain carries autosomes from the normo-
tensive WKY strain and the Y chromosome from the hypertensive
SHR. The SHR/a strain carries autosomes from the SHR strain and
the Y chromosome from the normotensive WKY strain.18 The
animals were housed in groups of 2 to 3 in a polyethylene cage
(45325320 cm) with a stainless steel top and heat-treated wood
chips for bedding (P.J. Murphy Forest Products). Rat chow (Teklad
Rodent diet) and water were provided ad libitum. All animals were
kept in environmentally controlled conditions of 25°C to 27°C, 40%
to 50% humidity, and a 12-hour light/dark cycle. A baseline blood
pressure from each animal was obtained 2 weeks before surgery by
tail-cuff sphygmomanometry to check that blood pressures were in
the right range for each strain: SHR (170 to 200 mm Hg), WKY (110
to 130 mm Hg), SHR/y (150 to 170 mm Hg), and SHR/a (150 to
170 mm Hg). If pressures were not in these ranges, the animals were
not used. The present animals were 1 generation removed (F16) from
animals in which blood pressure was measured by aortic telemetry
(F17) and should have had comparable pressures (SHR, 195 mm Hg;
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WKY, 122 mm Hg; SHR/y, 152 mm Hg; SHR/a, 155 mm Hg12). All
procedures and tests were in accordance with the American Physi-
ological Society statement on the humane treatment of animals and
were approved by The University of Akron Institutional Animal Care
and Use Committee.
The experimental design for the study used 84 castrated rats and
involved the following 3 treatments and 4 strains: sham implants in
WKY (n57), SHR (n56), SHR/y (n55), and SHR/a (n57); 1
testosterone implant in WKY (n56), SHR (n511), SHR/y (n58),
and SHR/a (n59); and 2 testosterone implants in WKY (n56), SHR
(n56), SHR/y (n57), and SHR/a (n56).
Castration, Testosterone Implants, and
Kidney Retrieval
Animals were sedated with 50 mg/kg Brevital (Eli Lilly & Co) and
surgically castrated. Testosterone implants were composed of Silas-
tic tubing (Dow Corning Midland) with a length of 19 mm (ID,
0.062 mm; OD, 0.125 mm), containing 10 mg testosterone propi-
onate. The ends were sealed with Silastic medical-grade silicone
adhesive (Type A, Dow Corning).19 Before implantation, the im-
plants were cured overnight in 5% bovine serum albumin,
10 mmol/L sodium phosphate buffer, 0.9% NaCl, and 0.0001%
merthiolate and soaked in 70% ethanol for 2 hours. Two weeks after
testosterone implantation, the animals were again sedated (50 mg/kg
Brevital), and a retro-orbital blood sample was taken before kidney
retrieval to determine serum testosterone levels.20 The serum samples
were collected retro-orbitally immediately before kidney isolation
and analyzed by radioimmunoassay for testosterone concentration
(Bio-Rad Laboratories). The correlation with another kit was
r50.991, sensitivity was 0.08 ng/mL at the 95% confidence limit,
and the highest cross-reactivity with potential interfering steroids
was with 5a-dihydrotestosterone (6.65%). The coefficient of varia-
tion for our sample range within-run was 7.4% to 11.6% and for
between-run was 12.5% to 16.96%.
Animals were heparinized (1000 U/cc) and then sedated with
Brevital for kidney removal. The body cavity was opened, and the
left and right adrenal glands were isolated and removed. Adipose and
connective tissues around the left kidney were removed so they
would not adhere to the kidney and interfere with the stimulation
procedure. The vessels branching off the aorta in the region were
isolated and ligated. The main bifurcation of the aorta between the
left and right kidneys, along with the placement of ligatures at the
posterior end of the aorta proximal to the femoral bifurcation, were
to aid in organ removal. The kidneys were removed, and a 21-gauge
blunted needle was secured in the aorta for retrograde perfusion of
the left kidney. The ischemic time from aortic ligation to start of
isolated kidney perfusion was ,1 minute. The right kidney was
frozen and stored at 270°C for later NE analysis. The animal was
then terminated with a bolus injection of Brevital directly into the
heart. The 21-gauge needle supporting the aorta and kidney was
suspended and perfused using a Gilson pump (minipuls 2) at a rate
of 6 mL/min. The pressure was monitored through a Statham gauge
pressure transducer (model P23 ID) attached to a Gould physiograph
(model 2400S). The pressure of the unstimulated perfused kidney
was an average of 50 mm Hg and during stimulation rose to an
average of 100 mm Hg. Krebs solution composed of 119 mmol/L
NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2 mmol/L MgSO4,
1.2 mmol/L KH2PO4, 25 mmol/L NaHCO3, and 14 mmol/L dextrose
was oxygenated with 95% O2/5% CO2 and warmed and maintained
at 35°C on a stir plate. The kidney was allowed to equilibrate until
a constant pressure was achieved.
Perfusate Assay for NE and
Lactate Dehydrogenase
Two samples of renal perfused fluid were collected at 5 time points:
the first collection (1 mL) was for lactate dehydrogenase (Sigma
Chemical Co) to determine the level of tissue damage obtained
through the removal and perfusion of the kidney, and the second
collection (6 mL) was to determine the levels of NE present using
high-performance liquid chromatography with electrochemical de-
tection (HPLC-ELD).21 The first collection was a steady-state control
with normal Krebs solution (4.7 mmol/L KCl) 7 minutes after
pressure equilibrium had been achieved. The kidney was then
perfused with Krebs solution containing 15 mmol/L KCl to poten-
tiate the potassium channels and facilitate vasoconstriction. The
kidney was stimulated at the base of the renal artery (Grass
Stimulator, model 5D9) with a frequency of 4 cps, duration of 4
milliseconds, and intensity of 18 V. The stimulus was applied for 1
minute. Therefore, 5 collections for NE were taken: the first sample
was for the control, the middle sample was used for the representa-
tive stimulated sample, and the final sample was another control. The
second and fourth samples were not used. Each collection for NE
was stabilized in a solution of mobile phase and immediately frozen
in liquid nitrogen; the NE samples were stored until analysis at
270°C. The first perfusate collection was a control sample without
stimulation, followed by 3 stimulation periods with a 7-minute
equilibration period between each, during perfusion with normal
Krebs solution; a final control perfusate was collected with no
electrical or potassium stimulation. The average length of time for
sample collection was about 70 seconds for 7 mL, and the average
total time for a kidney experiment once perfusion was complete was
'35 minutes.
Kidney Homogenization
After the perfusion experiments, the left kidney was weighed and
adipose tissue was removed. Each kidney was placed in a glass
specimen jar with 2 mL of mobile phase (0.035 mol/L citric acid
monohydrate, 0.09 mol/L sodium acetate, 130 mmol/L octylsulfate,
sodium salt, and 11% methanol) used in the HPLC assay. The
kidneys were homogenized (model m133/1281-0, Biospec Products
Inc) at 4°C to 6°C, transferred to a 12375-mm test tube, and
centrifuged (Damon/IEC division centrifuge model IE HN-SII) at
4°C to 6°C and 10 000 rpm for 10 minutes. The supernatant was
removed and stored in a microcentrifuge tube at 270°C for NE
analysis. Values for NE content and release are presented as absolute
values and fractional overflow ratios because the right kidney was
used for content analyses (total NE) and the left kidney for the
isolation perfusion studies.
The statistical analysis included 1- and 2-way ANOVAs and
appropriate follow-up t tests using Sigma Stat (Jandel Scientific).
Significance was assumed if P,0.05.
Results
Serum testosterone levels were significantly different among
implant groups: sham, single implants, and double implants
Figure 1. Blood serum testosterone levels by strain 2 weeks
after implantation (means and bars indicate standard error,
2-way ANOVA): strain, F51.10, NS; implant, F5119.9, P,0.001;
interaction, F50.9, NS. **P,0.01, ***P,0.001 compared with
previous bar, t test.
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(F5120, P,0.001), and the t tests showed significant differ-
ences (P,0.05) within strains among treatment groups (Fig-
ure 1). There were no significant differences among strains
and no interaction between treatment and strain. Lactate
dehydrogenase levels in the kidney perfusate were low, with
an average of 7 U/L, which indicates minimal cellular
damage.
Figure 2 shows an increase in the release of NE in the
perfusate from the left kidney. The NE release data are pooled
across all 4 strains to illustrate the general effect of the
testosterone. This increase in NE release was associated
directly with the level of testosterone present (sham, 450
pg/mL; single implant, 580 pg/mL; or double implant, 750
pg/mL) and demonstrated a significant increase in the release
of NE between implants (ANOVA, F5130, P,0.0001).
In WKY, electrical stimulation increased renal NE over-
flow significantly compared with the control values, but
testosterone did not further increase it. In contrast, in SHR/y
rats there was a significant enhancement of renal NE over-
flow with testosterone treatment during stimulation (Figure
2). There were similar increases in renal NE overflow during
stimulation without significant testosterone enhancement in
SHR/a, whereas the SHR group showed testosterone
enhancement.
Kidney NE content in the right nonperfused control was
examined in all 4 strains of rats (Figure 3). The comparison of
strains, treatments, and the NE content for the right kidney
showed that the SHR/y was the highest compared with the
WKY group.
The comparison of all strains, implant type, and NE
content showed a significant difference between the WKY
and SHR/y right control kidney (P50.004). There were no
significant differences found among the other strains. The
Table shows the percentage of stimulus-induced fractional
overflow of renal NE, which is based on the amount released
compared with the total content of the right kidney that was
not stimulated. This assumes that both kidneys have approx-
imately the same NE content. From a previous study in our
laboratory, we found there were no differences in NE content
Figure 3. Kidney NE content by strain and treatment in the con-
trol nonperfused right kidney after castration and 2-week
implantation with testosterone propionate or sham implants.
Two-way ANOVA: strain, F56.437, P,0.01; treatment, F50.178,
NS; interaction, F53.818, P50.01. **P50.004 WKY vs SHR/y
right control implant; 11P,0.01 for SHR/y sham vs implant
(mean6SE).
Stimulus-Induced Fractional Overflow Percentage of
Renal Norepinephrine
Treatment WKY SHR/y SHR SHR/a
Sham castrated
control
0.7460.15 0.4860.07 0.3160.04 0.6060.15
Testosterone implant 0.7060.10 0.7560.09* 0.7560.13* 0.6660.38
Increase, % 25 56 142 10
Values are mean6SEM.
*P,0.05 testosterone implant compared with castrated sham control.
Figure 2. Renal NE after castration and 2-week
implantation with testosterone propionate or
sham implants. A, WKY and SHR/y: control vs
sham, ***P,0.001; sham vs testosterone SHR/y,
***P,0.0001; WKY vs SHR/y testosterone,
11P,0.01. B, SHR and SHR/a: control vs
sham, **P,0.05, ***P,0.001; sham vs testoster-
one in SHR, ***P,.001. Values are mean6SE
(control periods are before and after stimulation).
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or release from the left versus right kidney (L. Eveleth,
unpublished results, 1996). Testosterone increased the frac-
tional NE release in SHR and SHR/y (P,0.05) but not in
SHR/a or WKY. SHR/y showed a greater fractional release
than SHR/a but not as high as that of SHR.
Discussion
The SHR Y chromosome (present in the SHR and SHR/y
groups) was associated with increased renal NE release in
the presence of testosterone compared with the response
associated with the WKY Y chromosome (present in the
WKY and SHR/a groups). Previously, we showed that the
presence of androgens and their receptors was necessary
for the maximum effect of the Y chromosome on blood
pressure.22 Testosterone most likely was the main steroid
responsible for the blood pressure effect because castration
reduced blood pressure, and testosterone replacement after
castration restored blood pressure to control levels.19,22,23
However, not as much is known about the interaction of
NE and testosterone. Testosterone can influence NE me-
tabolism, storage, and release.24 For instance, long-term
castration decreases the density of adrenergic neurons and
produces morphological changes that are reversed with
testosterone replacement.25 Androgenic hormones can in-
duce and/or maintain the sensitivity of the a2-adrenergic
receptor system in the Wistar rat and may be involved in
the maturation of the system.26 However, this would seem
contradictory to our results because this would reduce NE
overflow. Different tissues and different rat strains may
respond differently. Inhibition of NE uptake by testoster-
one has been shown in the isolated rat heart.27 Testosterone
has been shown to stimulate the increased expression of
a1-receptors in myocytes grown in tissue culture after 48 to
96 hours because of synthesis of new proteins.28 In the
central nervous system, peripheral testosterone also mod-
ulates NE metabolism. For instance, testosterone implants
similar to those used in our study reduced NE turnover in
the basal hypothalamus.29 Also, the presence of testoster-
one significantly potentiates the vasopressor action of
NE,30 and in castrated rats potassium-stimulated NE re-
lease was reduced in olfactory bulbs31 compared with that
in intact animals. One of the primary interactions of
testosterone and NE is testosterone regulation of tyrosine
hydroxylase, the rate-limiting step in the biosynthesis of
catecholamines found in the superior cervical ganglia.32
Activation of the renal adrenergic receptor increases so-
dium reabsorption by promoting Na1-H1 exchange at the
brush border of renal tubules.33 Because the presence of the
Y chromosome in the SHR/y animals produced an early
rise in testosterone levels and was associated with a rise in
blood pressure34 and elevated sympathetic nervous system
indices,12 which approach those of SHR, it appears possi-
ble that the Y chromosome, through both enhanced SNS
activity and an earlier testosterone rise, may cause more
NE to be released from the kidney.
The SHR has increased SNS activity5,6,9,19 that can lead
to increased circulating NE,12,19 which has been implicated
in the genesis of hypertension. The testosterone-induced
increase in renal NE release (125% to 167%) was seen in
both groups with an SHR Y chromosome (SHR and SHR/y
animals), possibly due to increased NE stores and more
release per stimulation. The percentage of increase of NE
release after testosterone treatment was highest in SHR,
followed by SHR/y and then SHR/a, which supports the
idea that the Y chromosome influences NE release. The
WKY group and the SHR/a strain without the SHR Y
chromosome did not show significant testosterone en-
hancement of renal NE release. Our data suggest that the
increased NE release is probably due to increased NE
stores in SHR/y because they had an 86% increase in NE
content compared with WKY, which is about half the total
increase in NE release (167%). We expected the SHR
group to also have elevated renal NE stores, which the
castrated group did, but testosterone treatment did not
significantly raise the NE content in any group except
SHR/y, which appears to be due to increased NE release.
Because testosterone treatment did not increase renal NE
content of SHR but did increase the NE overflow, this
suggests a different additional mechanism operating in the
SHR/y, perhaps functioning at the biosynthetic enzyme
level.
The testosterone enhancement of renal NE release is
supported by our recent findings that the Y chromosome
produces enhanced SNS activity with increased adrenal
gland chromogranin A, which represents a long-term SNS
influence.12 The precise mechanism for this NE elevation
in adrenal storage is not known but could be due to an
increase in synthesis; future studies we are planning will
examine the rate-limiting enzyme in the catecholamine
pathway, tyrosine hydroxylase. There is also evidence
supporting the idea that NE can significantly stimulate
testicular testosterone in a concentration-dependent man-
ner.35 Even metabolic enzymes such as ornithine decarbox-
ylase are regulated by steroids and catecholamines,36 and
recently testosterone regulation of renal proximal tubule
organic anion-transporting polypeptide (oatp) has been
shown in the Sprague-Dawley rat.37 Their results suggest
that oatp may play a role in the metabolic clearance and
elimination of endogenous sex steroid hormones. Andro-
gen receptors have been identified in the kidney proximal
tubules38; their function is not yet known but may involve
electrolyte regulation.
The role of the kidney in hypertension is complex,
involving physical, neural, and neuroendocrine regula-
tion.39 An excellent review by Di Bona and Kopp40 details
the complex involvement of the SNS and kidney function.
The increased activation of the SNS could contribute to
renal hypertension via several mechanisms, including in-
creased catecholamine biosynthesis and release, and/or via
central actions of angiotensin II, which can increase
sympathetic nerve activity and elevate blood pressure.41
Sympathetic nerve endings possess prejunctional receptors
that can be activated by chemical factors to increase or
inhibit NE release.42 Also, a-adrenoceptor blockade–resis-
tant pressor responses in the rat kidney are due to the
sympathetic cotransmitter ATP.43 There is an increased
a2-adrenoceptor–mediated autoregulation of NE release in
SHR kidneys caused by increased intrasynaptic NE.44
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The increase in SNS activity in SHR and SHR/y animals
also could be reflected in changes in gene expression that
occur through receptor-mediated events involving both NE
and its effect on other hormones. It has been proposed that
angiotensin II interacts with the SNS to facilitate NE
release in the kidney.45 Renal denervation has been shown
to delay the onset or decrease the severity of renal
hypertension46,47 and results in a major reduction in renal
NE content in SHR and WKY.47 Dihydrotestosterone also
has been shown to have a tissue-specific regulation of
renin mRNA in several organs important for blood pres-
sure control, eg, the kidney, adrenal gland, and brain in
female mice.48 There also appears to be a testosterone-
renin-angiotensin interaction that shows a direct relation-
ship between androgens and renal and hepatic, angioten-
sinogen, and renin mRNA in hypertensive rats.49
In conclusion, testosterone significantly increased renal
NE release in the 2 strains with the SHR Y chromosome
(SHR and SHR/y) but not in the 2 strains with the WKY Y
chromosome (WKY and SHR/a). Because the SHR/y
group treated with testosterone also had increased NE
renal storage, the data support the hypothesis that the Y
chromosome effect facilitates the action of testosterone on
NE release. This influence on renal function may account
for a portion of the blood pressure rise associated with the
SHR Y chromosome.
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